I've been pondering that question myself @muppet655
Based on my rough figures from their latest (RAP) presentation:
A bulletproof diagnosis tool (so far -so assuming this translates to adults)
currently 22.5million telehealth consults per year on respiratory issues (growing at 56% per year)
a possible per use charge of $10.
Suggests a current revenue of $22.5Billion per year. and with growth of 56%p.a. would suggest a pretty healthy forward PE.
OK, so i'm being wildly optimistic and lets hope the results with the expanded patient set continue to look so strong...but it does start to beg the question about who will be bigger in the long run out of AJX and RAP.
Personally i think its akin to asking a parent to choose between their two children...i love them both!!!
AJX Price at posting:
79.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)